Full year 2022 total revenue is expected to be in the range of $71.2M to $71.4M, an increase of 46% compared to the prior year at the estimated midpoint. "We are pleased with the strong performance across our entire business in 2022," said Paul Badawi, Founder and Chief Executive Officer of Sight Sciences. "Our progress this year reinforced that our OMNI Surgical System, TearCare System and now our SION Surgical Instrument are each category-leading and differentiated solutions with the potential to not only continue taking significant market share but also, and perhaps more importantly, expand very large markets in glaucoma and dry eye. Looking ahead to 2023, we believe that we are well positioned to drive sustained growth through increasing adoption and utilization of our Surgical Glaucoma and Dry Eye products."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGHT:
- Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
- Stifel upgrades Sight Sciences to Buy on potential 2023 upside
- Sight Sciences upgraded to Buy from Hold at Stifel
- Sight Sciences, Verana Health collaborate on glaucoma research
- Sight Sciences price target raised to $15 from $10 at Citi
